Medical/Pharmaceuticals

Positive results from first-in-human completely leadless CRT in the US, published in The Journal of the American College of Cardiology

SUNNYVALE, Calif., Oct. 25, 2023 /PRNewswire/ -- EBR Systems, Inc. (ASX:EBR), the medical device company developing wireless cardiac pacing systems, is proud to announce that positive results from the first completely leadless cardiac resynchronization therapy (CRT) ...

2023-10-26 00:00 1822

Neuragenex Brings Innovative Fibromyalgia Treatment to Patients Across the US

GULBERT, Ariz., Oct. 25, 2023 /PRNewswire/ -- Neuragenex, the national healthcare provider focused on non-pharmaceutical pain treatment, announced its continued expansion to bring relief to fibromyalgia patients across the country. With clinics now operating in Georgia, Texas, Illinois, Tenness...

2023-10-25 23:23 1368

Qilu Pharmaceutical announces the latest results from its clinical study on QL1706, in combination with chemotherapy, as a first-line treatment for recurrent or metastatic cervical cancer

JINAN, China, Oct. 25, 2023 /PRNewswire/ -- On October 22, Qilu Pharmaceutical unveiled the latest findings from a multicenter, single-arm Phase II clinical trial at the European Society for Medical Oncology (ESMO) Annual Congress 2023. This trial studied the use of QL1706 (iparomlimab and tuvonr...

2023-10-25 22:15 1944

First Patient Dosed for MRCT Phase 3 Study on First-Line LS-SCLC of Henlius Anti-PD-1 mAb Serplulimab in Europe

SHANGHAI, Oct. 25, 2023 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the first patient inEurope has been dosed in the international multi-centre phase 3 clinical trial (NCT05353257) of the company's self-developed anti-PD-1 mAb HANSIZHUANG (serplulimab) in combination ...

2023-10-25 21:15 1962

Good Safety Profile and Antitumor Activity: Oral Presentation of Mabwell's 9MW2821 at 2023 ESMO

Shanghai, Oct. 25, 2023 /PRNewswire/ -- ESMO Congress 2023 was held in Madrid, Spain from October 20-24, the preliminary results of the Phase I/II study of 9MW2821 (Nectin-4 targeting ADC) in patients with advanced solid tumors were reported by Dr.Jian Zhang of Fudan University Shanghai Cancer Ce...

2023-10-25 17:46 1674

GC Cell Joins U.S Cancer Moonshot Project

Brining Expertise in NK Cell Therapy to Advance Efforts in Cancer Prevention, early detection, and treatment development ▶ New focus on NK cell therapy for conquering cancer ▶ GC Cell seizes the opportunity to share its cell gene therapy technology and capabilities globally ▶ Development of sol...

2023-10-25 11:27 1662

First Immunotherapy Success in TKI-Resistant Lung Cancer Setting Demonstrates Power of AI-driven Immune Phenotyping by Lunit SCOPE IO - newly published in JCO

* Lunit SCOPE IO pivotal in first phase III trial successfully showing the efficacy of immunotherapy + chemotherapy for NSCLC patients with EGFR or ALK mutation - published in theJournal of Clinical Oncology and accepted by ESMO for oral presentation SEOUL, South Korea, Oct. 24, 2023 /PRNewswir...

2023-10-24 21:00 1614

Phase Ib/II Results of Akeso's PD-1/CTLA-4 Bispecific Antibody for First-Line Treatment of Advanced Hepatocellular Carcinoma Published at 2023 ESMO

HONG KONG, Oct. 24, 2023 /PRNewswire/ -- Akeso announced poster presentation at the 2023 European Society for Medical Oncology (ESMO) Congress from its cadonilimab ( PD-1/CTLA-4 bispecific antibody) combined with lenvatinib for first-line treatment of Advanced Hepatocellular Carcinoma (HCC). The ...

2023-10-24 20:00 1296

Clinical Trial Application (IND) for BioRay Pharmaceutical's BR105 Injection Receives U.S. FDA Approval

SHANGHAI, Oct. 24, 2023 /PRNewswire/ -- BioRay Pharmaceutical Co., Ltd. (hereinafter referred to as "BioRay") announced onOctober 7th that its clinical trial application for BR105 Injection has received approval from the United States Food and Drug Administration (FDA). This marks BioRay's first ...

2023-10-24 15:05 1233

OBiO Announces Strategic Partnership with Refreshgene to Realize Commercialization of Gene Therapy Product

Visit OBiO at ESGCT 30th Annual Congress in Brussels SHANGHAI, Oct. 24, 2023 /PRNewswire/ -- OBiO Technology (Shanghai) Corp., Ltd. (OBiO, 688238.SH), a world leading contract development and manufacturing organization for cell and gene therapy, officially announced an agreement with Refreshgene...

2023-10-24 12:05 1553

Wingderm® Has Unveiled the Latest Research of Mesoskin for Mesotherapy Treatment at AMWC

BEIJING, Oct. 23, 2023 /PRNewswire/ -- On October 20-22, 2023, the Aesthetic & Anti-Aging Medicine World Congress (AMWC) was held inChengdu, China. A wide range of aesthetic plastic surgery products and technologies made their appearance at this event, Wingderm®'s Latest Research of Mesoskin for ...

2023-10-24 09:23 1421

Genesis MedTech initiates enrollment in its North American Early Feasibility Study using the J-Valve™ Transfemoral System for patients with severe aortic regurgitation

BURLINGAME, Calif., Oct. 23, 2023 /PRNewswire/ -- Genesis MedTech, a leading medical device company, today announced initiation of enrollment in its North American Early Feasibility Study using its dedicated TAVR system, J-Valve™ Transfemoral (TF) System. The procedure was successfully perform...

2023-10-23 22:00 1764

Certa Therapeutics' FT011 Granted US FDA Orphan Drug Designation for the Treatment of Systemic Sclerosis

MELBOURNE, Australia, Oct. 23, 2023 /PRNewswire/ -- Certa Therapeutics (Certa), a biotechnology company developing innovative precision therapies for patients with inflammatory and fibrotic diseases, today announces that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation ...

2023-10-23 21:30 1409

WAT Medical Donates to the Canadian Red Cross and Peach Arch Hospital

VANCOUVER, BC, Oct. 23, 2023 /PRNewswire/ -- WAT Medical Enterprise Ltd. has extended its support to two prominent institutions: the Canadian Red Cross and Peach Arch Hospital, throughmonetary donations. WAT Medical Enterprise Ltd. is a leading ...

2023-10-23 21:00 1747

AI Diagnostic Platform Company Noul, unveils the result of Malaria study in Ethiopia and Ghana

* Reaffirming innovation as an AI-based digital microscope while presenting new malaria data at the annual meeting of the ASTMH 2023 * Noul's 'miLab™' showed significantly higher sensitivity than that of microscopy in health centers YONGIN, South Korea, Oct. 23, 2023 /PRNewswire/ -- Noul Co.,...

2023-10-23 21:00 1761

VUNO Secures FDA 510(k) Clearance for VUNO Med®-DeepBrain®

SEOUL, South Korea, Oct. 23, 2023 /PRNewswire/ -- VUNO Inc., South Korean medical AI company has received 510(k) clearance from the Food and Drug Administration (FDA) for its AI-powered brain quantification device, VUNO Med®-DeepBrain®.

2023-10-23 21:00 1964

Zhongchao Inc. Launches Breast Cancer Follow-up Visit and Health Management Patient Guide Program on Breast Cancer Awareness Day

SHANGHAI, Oct. 23, 2023 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services for patients with cancer and other major diseases, today announced that its Zhongxin platform  launched a WeChat mini program of Bre...

2023-10-23 20:00 1369

Live from ESMO 2023 | Oral Report Featuring Latest Data of Pelcitoclax (APG-1252) Combined with Osimertinib Demonstrates Potential as a New Treatment Option for TP53-and EGFR-Mutant NSCLC

SUZHOU, China and ROCKVILLE, Md., Oct. 23, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released the latest clinical data of it...

2023-10-23 19:56 1307

Mabwell Announces Latest Clinical Progress and Data to be Reported on ESMO 2023 of 2 Novel Drugs

SHANGHAI, Oct. 23, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announces the latest clinical progress of 2 novel drugs including Nectin-4 ADC 9MW2821, as well as the clinical study data to be reported on ESMO 2023. Latest progress...

2023-10-23 18:25 1421

JINGHAO MEDICAL's self-fitting OTC hearing aids received FDA 510(k) approval

HONGKONG, SHANGHAI, and BEIJING, Oct. 23, 2023 /PRNewswire/ -- As the first hearing aid manufacturer to be listed in China, JINGHAO MEDICAL has once again taken a historic step. OnSeptember 26, 2023, the self-fitting OTC hearing aid developed and manufactured by JINGHAO MEDICAL officially receive...

2023-10-23 18:01 1330
1 ... 54555657585960 ... 214

Week's Top Stories